| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:BCL2L11_MERTK |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: BCL2L11_MERTK | KinaseFusionDB ID: KFG582 | FusionGDB2.0 ID: KFG582 | Hgene | Tgene | Gene symbol | BCL2L11 | MERTK | Gene ID | 10018 | 10461 | |
| Gene name | BCL2 like 11 | MER proto-oncogene, tyrosine kinase | ||||||||||
| Synonyms | BAM|BIM|BOD | MER|RP38|Tyro12|c-Eyk|c-mer | ||||||||||
| Cytomap | 2q13 | 2q13 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | bcl-2-like protein 11BCL2-like 11 (apoptosis facilitator)bcl-2 interacting mediator of cell deathbcl-2 interacting protein Bimbcl-2-related ovarian death agonist | tyrosine-protein kinase MerMER receptor tyrosine kinaseSTK kinasec-mer proto-oncogene tyrosine kinaseproto-oncogene c-Merreceptor tyrosine kinase MerTK | ||||||||||
| Modification date | 20240411 | 20240411 | ||||||||||
| UniProtAcc | O43521 | Q12866 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000308659, ENST00000357757, ENST00000393253, ENST00000393256, ENST00000337565, ENST00000405953, | ENST00000295408, ENST00000409780, ENST00000421804, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: BCL2L11 [Title/Abstract] AND MERTK [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | BCL2L11(111907724)-MERTK(112751827), # samples:1 BCL2L11(111907724)-MERTK(112751828), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | BCL2L11 | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 11546872 |
| Hgene | BCL2L11 | GO:0031334 | positive regulation of protein-containing complex assembly | 21041309 |
| Hgene | BCL2L11 | GO:0034976 | response to endoplasmic reticulum stress | 22761832 |
| Hgene | BCL2L11 | GO:0042981 | regulation of apoptotic process | 18209102 |
| Hgene | BCL2L11 | GO:2000271 | positive regulation of fibroblast apoptotic process | 11997495 |
| Tgene | MERTK | GO:0050766 | positive regulation of phagocytosis | 18395422 |
| Kinase Fusion gene breakpoints across BCL2L11 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Kinase Fusion gene breakpoints across MERTK (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-DQ-7594 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751827 |
| ChimerDB4 | TCGA-DQ-7594 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751828 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
| ENST00000393253 | ENST00000295408 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751827 | 2917 | 697 |
| ENST00000393253 | ENST00000295408 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751828 | 2917 | 697 |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq >ENST00000393253_ENST00000295408_BCL2L11_chr2_111907724_MERTK_chr2_112751827_length(amino acids)=697 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPA HGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEE LQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQ GIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGD YYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPL DRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILN -------------------------------------------------------------- >ENST00000393253_ENST00000295408_BCL2L11_chr2_111907724_MERTK_chr2_112751828_length(amino acids)=697 MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPA HGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEE LQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQ GIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGD YYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPL DRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILN -------------------------------------------------------------- |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr2:111907724/chr2:112751827) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| BCL2L11 | MERTK |
| FUNCTION: Induces apoptosis and anoikis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than isoform BimEL, isoform BimL and isoform BimS. Isoform Bim-gamma induces apoptosis. Isoform Bim-alpha3 induces apoptosis possibly through a caspase-mediated pathway. Isoform BimAC and isoform BimABC lack the ability to induce apoptosis. {ECO:0000269|PubMed:11997495, ECO:0000269|PubMed:15486195, ECO:0000269|PubMed:15661735, ECO:0000269|PubMed:9430630}. | FUNCTION: Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to several ligands including LGALS3, TUB, TULP1 or GAS6. Regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). Ligand binding at the cell surface induces autophosphorylation of MERTK on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with GRB2 or PLCG2 and induces phosphorylation of MAPK1, MAPK2, FAK/PTK2 or RAC1. MERTK signaling plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment (PubMed:32640697). Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. Also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. {ECO:0000269|PubMed:17005688, ECO:0000269|PubMed:32640697}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| Tgene | BCL2L11 | 111907724 | MERTK | 112751827 | ENST00000393253 | 7 | 19 | 587_858 | 432 | 1000 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | BCL2L11 | 111907724 | MERTK | 112751827 | ENST00000393253 | 7 | 20 | 587_858 | 432 | 951 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | BCL2L11 | 111907724 | MERTK | 112751828 | ENST00000393253 | 7 | 19 | 587_858 | 432 | 1000 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
| Tgene | BCL2L11 | 111907724 | MERTK | 112751828 | ENST00000393253 | 7 | 20 | 587_858 | 432 | 951 | Domain | Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159 |
Top |
Kinase Fusion Protein Structures |
| CIF files of the predicted kinase fusion proteins * Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format. |
| Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB) | Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | AA seq | Len(AA seq) |
| PDB file >>>56_BCL2L11_MERTK | ENST00000393253 | ENST00000295408 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751828 | MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPA HGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEE LQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQ GIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGD YYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPL DRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILN | 697 |
| 3D view using mol* of 56_BCL2L11_MERTK | ||||||||||
| PDB file >>>TKFP_81_BCL2L11_MERTK | ENST00000393253 | ENST00000295408 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751827 | MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPA HGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEE LQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQ GIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGD YYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPL DRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILN | 697_BCL2L11_MERTK |
| PDB file >>>TKFP_82_BCL2L11_MERTK | ENST00000393253 | ENST00000295408 | BCL2L11 | chr2 | 111907724 | MERTK | chr2 | 112751828 | MQPPCEPCHTAIASSRYSVRCVPAATASAPFLGPCSPKCLTLTLGLRNARKKDQMAKQPSDVSSECDREGRQLQPAERPPQLRPGAPTSL QTEPQASMRQAEPADMRPEIWIAQELRRIGDEFNAYYARRKELLEEVGQNGSRARISVQVHNATCTVRIAAVTRGGVGPFSDPVKIFIPA HGWVDYAPSSTPAPGNADPVLIIFGCFCGFILIGLILYISLAIRKRVQETKFGNAFTEEDSELVVNYIAKKSFCRRAIELTLHSLGVSEE LQNKLEDVVIDRNLLILGKILGEGEFGSVMEGNLKQEDGTSLKVAVKTMKLDNSSQREIEEFLSEAACMKDFSHPNVIRLLGVCIEMSSQ GIPKPMVILPFMKYGDLHTYLLYSRLETGPKHIPLQTLLKFMVDIALGMEYLSNRNFLHRDLAARNCMLRDDMTVCVADFGLSKKIYSGD YYRQGRIAKMPVKWIAIESLADRVYTSKSDVWAFGVTMWEIATRGMTPYPGVQNHEMYDYLLHGHRLKQPEDCLDELYEIMYSCWRTDPL DRPTFSVLRLQLEKLLESLPDVRNQADVIYVNTQLLESSEGLAQGSTLAPLDLNIDPDSIIASCTPRAAISVVTAEVHDSKPHEGRYILN | 697_BCL2L11_MERTK |
Top |
Comparison of Fusion Protein Isoforms |
| Superimpose the 3D Structures Among All Fusion Protein Isoforms * Download the pdb file and open it from the molstar online viewer. |
| Comparison of the Secondary Structures of Fusion Protein Isoforms |
Top |
Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB |
Top |
pLDDT score distribution |
| pLDDT score distribution of the predicted fusion protein structures from AlphaFold2 * AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. * The blue color at the bottom marks the best active site residues. |
| 56_BCL2L11_MERTK.png |
 |
| 56_BCL2L11_MERTK.png |
 |
Top |
Potential Active Site Information |
| The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite. |
| Kinase Fusion AA seq ID in KinaseFusionDB | Site score | Size | Dscore | Volume | Exposure | Enclosure | Contact | Phobic | Philic | Balance | Don/Acc | Residues |
Top |
Ramachandran Plot of Kinase Fusion Protein Structure |
| Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide. |
| 56_BCL2L11_MERTK_ramachandran.png |
 |
Top |
Virtual Screening Results |
| Distribution of the average docking score across all approved kinase inhibitors. Distribution of the number of occurrence across all approved kinase inhibitors. |
| 5'-kinase fusion protein case |
| 3'-kinase fusion protein case |
 |
Top |
| Drug information from DrugBank of the top 20 interacting small molecules. * The detailed information of individual kinase inhibitors are available in the download page. |
| Fusion gene name info | Drug | Docking score | Glide g score | Glide energy |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Tepotinib | -7.0469 | -7.047999999999999 | -56.2369 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Lapatinib | -6.6411 | -6.7299 | -61.4028 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Fedratinib | -6.5452 | -6.5966 | -56.0369 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Fedratinib | -6.5452 | -6.5966 | -56.0369 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Netarsudil | -6.51702 | -6.5281199999999995 | -50.4522 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Netarsudil | -6.51702 | -6.5281199999999995 | -50.4522 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Larotrectinib | -6.21569 | -6.21569 | -43.0393 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Entrectinib | -6.20355 | -6.26825 | -50.9985 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Entrectinib | -6.20355 | -6.26825 | -50.9985 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Brigatinib | -6.11695 | -6.13045 | -54.9962 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Brigatinib | -6.11695 | -6.13045 | -54.9962 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Lapatinib | -6.0418199999999995 | -6.1306199999999995 | -62.3275 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Fostamatinib | -6.0349 | -6.0985 | -53.1989 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Fostamatinib | -6.0349 | -6.0985 | -53.1989 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Ribociclib | -5.91153 | -5.98053 | -48.2631 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Ribociclib | -5.91153 | -5.98053 | -48.2631 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Vandetanib | -5.71189 | -5.71189 | -41.2111 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Abemaciclib | -5.63945 | -5.84155 | -39.9786 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Abemaciclib | -5.63945 | -5.84155 | -39.9786 |
| 56_BCL2L11_MERTK-DOCK_HTVS_1-001 | Abemaciclib | -5.63945 | -5.84155 | -39.9786 |
Top |
Kinase-Substrate Information of BCL2L11_MERTK |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MERTK | Q12866 | human | MLKL | Q8NB16 | Y376 | DRVkstAyLSPQELE | PK_Tyr_Ser-Thr |
| MERTK | Q12866 | human | AKT1 | P31749 | S473 | RPHFPQFsysAsGtA | Pkinase_C |
| MERTK | Q12866 | human | STAT5A | P42229 | Y694 | LAkAVDGyVkPQIkQ | |
| MERTK | Q12866 | human | STAT3 | P40763 | Y705 | DPGsAAPyLktKFIC | |
| MERTK | Q12866 | human | MERTK | Q12866 | Y749 | FGLsKKIysGDyyRQ | PK_Tyr_Ser-Thr |
| MERTK | Q12866 | human | STAT5B | P51692 | Y699 | tAkAVDGyVkPQIkQ | |
| MERTK | Q12866 | human | MERTK | Q12866 | Y754 | KIysGDyyRQGRIAk | PK_Tyr_Ser-Thr |
| MERTK | Q12866 | human | MERTK | Q12866 | Y753 | KKIysGDyyRQGRIA | PK_Tyr_Ser-Thr |
| MERTK | Q12866 | human | AKT1 | P31749 | T308 | kDGAtMKtFCGtPEy | Pkinase |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MERTK | ID | Description | 0.00e+00 |
| MERTK | GO:0060416 | response to growth hormone | 1.69e-07 |
| MERTK | GO:0060397 | growth hormone receptor signaling pathway via JAK-STAT | 7.95e-07 |
| MERTK | GO:0070669 | response to interleukin-2 | 7.95e-07 |
| MERTK | GO:0070672 | response to interleukin-15 | 7.95e-07 |
| MERTK | GO:0060396 | growth hormone receptor signaling pathway | 6.25e-06 |
| MERTK | GO:0071378 | cellular response to growth hormone stimulus | 6.25e-06 |
| MERTK | GO:0040014 | regulation of multicellular organism growth | 8.15e-05 |
| MERTK | GO:0071375 | cellular response to peptide hormone stimulus | 1.01e-04 |
| MERTK | GO:0048872 | homeostasis of number of cells | 1.01e-04 |
| MERTK | GO:0048638 | regulation of developmental growth | 1.06e-04 |
| MERTK | GO:1901653 | cellular response to peptide | 1.63e-04 |
| MERTK | GO:0001776 | leukocyte homeostasis | 2.26e-04 |
| MERTK | GO:0043434 | response to peptide hormone | 2.26e-04 |
| MERTK | GO:0001938 | positive regulation of endothelial cell proliferation | 2.26e-04 |
| MERTK | GO:0035723 | interleukin-15-mediated signaling pathway | 2.34e-04 |
| MERTK | GO:0071350 | cellular response to interleukin-15 | 2.34e-04 |
| MERTK | GO:0030879 | mammary gland development | 3.21e-04 |
| MERTK | GO:0035264 | multicellular organism growth | 4.10e-04 |
| MERTK | GO:0002262 | myeloid cell homeostasis | 6.12e-04 |
| MERTK | GO:0007259 | receptor signaling pathway via JAK-STAT | 6.12e-04 |
| MERTK | GO:0001936 | regulation of endothelial cell proliferation | 6.56e-04 |
| MERTK | GO:0097696 | receptor signaling pathway via STAT | 7.01e-04 |
| MERTK | GO:0001935 | endothelial cell proliferation | 8.31e-04 |
| MERTK | GO:0001779 | natural killer cell differentiation | 8.50e-04 |
| MERTK | GO:0050679 | positive regulation of epithelial cell proliferation | 9.61e-04 |
| MERTK | GO:0045648 | positive regulation of erythrocyte differentiation | 1.38e-03 |
| MERTK | GO:0070670 | response to interleukin-4 | 1.58e-03 |
| MERTK | GO:0043491 | phosphatidylinositol 3-kinase/protein kinase B signal transduction | 1.95e-03 |
| MERTK | GO:0007595 | lactation | 1.95e-03 |
| MERTK | GO:0071364 | cellular response to epidermal growth factor stimulus | 1.95e-03 |
| MERTK | GO:0045646 | regulation of erythrocyte differentiation | 2.19e-03 |
| MERTK | GO:0070849 | response to epidermal growth factor | 2.19e-03 |
| MERTK | GO:0043029 | T cell homeostasis | 2.22e-03 |
| MERTK | GO:0050878 | regulation of body fluid levels | 3.28e-03 |
| MERTK | GO:0050678 | regulation of epithelial cell proliferation | 4.39e-03 |
| MERTK | GO:0030098 | lymphocyte differentiation | 4.89e-03 |
| MERTK | GO:0030099 | myeloid cell differentiation | 4.89e-03 |
| MERTK | GO:0043536 | positive regulation of blood vessel endothelial cell migration | 4.94e-03 |
| MERTK | GO:0048732 | gland development | 4.94e-03 |
| MERTK | GO:0002260 | lymphocyte homeostasis | 4.94e-03 |
| MERTK | GO:0050673 | epithelial cell proliferation | 5.99e-03 |
| MERTK | GO:1903131 | mononuclear cell differentiation | 5.99e-03 |
| MERTK | GO:0007589 | body fluid secretion | 6.14e-03 |
| MERTK | GO:0010507 | negative regulation of autophagy | 6.14e-03 |
| MERTK | GO:0008593 | regulation of Notch signaling pathway | 7.10e-03 |
| MERTK | GO:0030101 | natural killer cell activation | 7.10e-03 |
| MERTK | GO:0045639 | positive regulation of myeloid cell differentiation | 7.52e-03 |
| MERTK | GO:0032355 | response to estradiol | 8.86e-03 |
| MERTK | GO:0062014 | negative regulation of small molecule metabolic process | 8.98e-03 |
Top |
Related Drugs to BCL2L11_MERTK |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning BCL2L11-MERTK and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to BCL2L11_MERTK |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |